BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...of Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc. hired former Five Prime Therapeutics Inc....
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

...with positive efficacy data for Five Prime’s bemarituzumab.Shares of Five Prime Therapeutics Inc....
...ORR) to prespecified statistical significance over chemotherapy alone. Five Prime...
...– Fibroblast growth factor receptor 2b isoform Lauren Martz Five Prime Therapeutics Inc. Zai...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...targeted cancer therapies to which Zai holds regional rights. They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc....
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...hired Lyndah Dreiling as SVP, clinical development. She was VP, head of clinical development at Five Prime Therapeutics Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...governance chair and therapeutic area head for oncology at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Five Prime Therapeutics Inc....
...CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...development of Perjeta pertuzumab, Avastin bevacizumab and Tecentriq atezolizumab. Irving was EVP and CSO at Five Prime Therapeutics Inc....
BioCentury | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

...Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to...
...Therapeutics Inc. , a cell therapy company he co-founded this year. Williams was CEO of Five Prime...
...global service organization at Illumina Inc. (NASDAQ:ILMN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Rubius Therapeutics Inc. Five Prime Therapeutics Inc. Replimune...
BioCentury | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

...is the managing director of biotech investment firm Woodside Way Ventures and was CMO of Five Prime Therapeutics Inc....
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...China) unit of Novartis AG (NYSE:NVS; SIX:NOVN). Aron Knickerbocker has stepped down as CEO of Five Prime Therapeutics Inc....
...Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge Pharmaceuticals Inc. Five Prime Therapeutics Inc....
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...potential in gastric cancer. Bemarituzumab (FPA144), the compound on which its Greater China deal with Five Prime Therapeutics Inc....
Items per page:
1 - 10 of 162
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...of Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc. hired former Five Prime Therapeutics Inc....
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

...with positive efficacy data for Five Prime’s bemarituzumab.Shares of Five Prime Therapeutics Inc....
...ORR) to prespecified statistical significance over chemotherapy alone. Five Prime...
...– Fibroblast growth factor receptor 2b isoform Lauren Martz Five Prime Therapeutics Inc. Zai...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...targeted cancer therapies to which Zai holds regional rights. They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc....
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...hired Lyndah Dreiling as SVP, clinical development. She was VP, head of clinical development at Five Prime Therapeutics Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...governance chair and therapeutic area head for oncology at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Five Prime Therapeutics Inc....
...CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...development of Perjeta pertuzumab, Avastin bevacizumab and Tecentriq atezolizumab. Irving was EVP and CSO at Five Prime Therapeutics Inc....
BioCentury | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

...Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to...
...Therapeutics Inc. , a cell therapy company he co-founded this year. Williams was CEO of Five Prime...
...global service organization at Illumina Inc. (NASDAQ:ILMN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Rubius Therapeutics Inc. Five Prime Therapeutics Inc. Replimune...
BioCentury | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

...is the managing director of biotech investment firm Woodside Way Ventures and was CMO of Five Prime Therapeutics Inc....
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...China) unit of Novartis AG (NYSE:NVS; SIX:NOVN). Aron Knickerbocker has stepped down as CEO of Five Prime Therapeutics Inc....
...Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge Pharmaceuticals Inc. Five Prime Therapeutics Inc....
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...potential in gastric cancer. Bemarituzumab (FPA144), the compound on which its Greater China deal with Five Prime Therapeutics Inc....
Items per page:
1 - 10 of 162